Literature DB >> 11193902

Dependence of anticancer activity of camptothecins on maintaining their lactone function.

B C Giovanella1, N Harris, J Mendoza, Z Cao, J Liehr, J S Stehlin.   

Abstract

Camptothecins contain a lactone ring that exists in the closed form below ph 7. Above 7, the open (CPT+) and the closed (CPT) form coexist in a 50-50 ratio in mouse plasma and in a 90-10 ratio in human plasma due to the high affinity of human serum albumin (HSA) for CPT+. CPT+ is much less toxic than CPT and it is excreted much faster. In complete RPMI 1640 culture medium, the equilibrium CPT(+)-CPT is 50-50. If 4% HSA is added, it moves to 90-10 modeling for the human physiological situation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193902     DOI: 10.1111/j.1749-6632.2000.tb07022.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Metabolic pathways of the camptothecin analog AR-67.

Authors:  Jamie Horn; Marta Milewska; Susanne M Arnold; Markos Leggas
Journal:  Drug Metab Dispos       Date:  2010-12-28       Impact factor: 3.922

2.  Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives.

Authors:  Guillermo Rodriguez-Berna; Maria Jose Díaz Cabañas; Victor Mangas-Sanjuán; Marta Gonzalez-Alvarez; Isabel Gonzalez-Alvarez; Ibane Abasolo; Simó Schwartz; Marival Bermejo; Avelino Corma
Journal:  ACS Med Chem Lett       Date:  2013-05-28       Impact factor: 4.345

3.  Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.

Authors:  Nilesh A Patankar; Dawn Waterhouse; Dita Strutt; Malathi Anantha; Marcel B Bally
Journal:  Invest New Drugs       Date:  2012-05-22       Impact factor: 3.850

4.  An HPLC assay for the lipophilic camptothecin analog AR-67 carboxylate and lactone in human whole blood.

Authors:  Eleftheria Tsakalozou; Jamie Horn; Mark Leggas
Journal:  Biomed Chromatogr       Date:  2010-10       Impact factor: 1.902

5.  CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.

Authors:  Serengulam V Govindan; Thomas M Cardillo; Sung-Ju Moon; Hans J Hansen; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

6.  Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.

Authors:  Sung-Ju Moon; Serengulam V Govindan; Thomas M Cardillo; Christopher A D'Souza; Hans J Hansen; David M Goldenberg
Journal:  J Med Chem       Date:  2008-10-22       Impact factor: 7.446

7.  A photo-activated targeting chemotherapy using glutathione sensitive camptothecin-loaded polymeric micelles.

Authors:  Horacio Cabral; Masataka Nakanishi; Michiaki Kumagai; Woo-Dong Jang; Nobuhiro Nishiyama; Kazunori Kataoka
Journal:  Pharm Res       Date:  2008-08-30       Impact factor: 4.200

8.  Diarylthiophenes as inhibitors of the pore-forming protein perforin.

Authors:  Christian K Miller; Kristiina M Huttunen; William A Denny; Jagdish K Jaiswal; Annette Ciccone; Kylie A Browne; Joseph A Trapani; Julie A Spicer
Journal:  Bioorg Med Chem Lett       Date:  2015-12-07       Impact factor: 2.823

9.  Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Authors:  David M Goldenberg; Thomas M Cardillo; Serengulam V Govindan; Edmund A Rossi; Robert M Sharkey
Journal:  Oncotarget       Date:  2015-09-08

10.  Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment.

Authors:  Nima Sepehri; Hasti Rouhani; Ahmad Reza Ghanbarpour; Mehdi Gharghabi; Faranak Tavassolian; Mohsen Amini; Seyed Nasser Ostad; Mohammad Hossein Ghahremani; Rassoul Dinarvand
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.